Abstract:The main protease (Mpro) of SARS-CoV-2 is a validated antiviral drug target. Several Mpro inhibitors have been reported with potent enzymatic inhibition and cellular antiviral activity, including GC376, boceprevir, calpain inhibitors II, and XII, with each containing a reactive warhead that covalently modifies the catalytic Cys145. Coupling structure-based drug design with the one-pot Ugi four-component reaction, we discovered one of the most potent noncovalent inhibitors, 23R (Jun8-76-3A) that is structurally distinct from the canonical Mpro inhibitor GC376. Significantly, 23R is highly selective compared with covalent inhibitors such as GC376, especially toward host proteases. The cocrystal structure of SARS-CoV-2 Mpro with 23R revealed a previously unexplored binding site located in between the S2 and S4 pockets. Overall, this study discovered 23R, one of the most potent and selective noncovalent SARS-CoV-2 Mpro inhibitors reported to date, and a novel binding pocket in Mpro that can be explored for inhibitor design.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00509?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00509</a>.Target selectivity of noncovalent inhibitor 23R; crystallographic statistics; H NMR and C NMR spectra for final products; HPLC traces for representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00509/suppl_file/jm1c00509_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00509/suppl_file/jm1c00509_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

De Novo Design of SARS-CoV-2 Main Protease Inhibitors with Characteristic Binding Modes

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

De novo Design of SARS-CoV-2 Main Protease Inhibitors

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease

De Novo design of potential inhibitors against SARS-CoV-2 Mpro

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors

Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease

Discovery of 3-Oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin Derivatives As SARS-CoV-2 Main Protease Inhibitors Through Virtual Screening and Biological Evaluation.

Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and its Variants Displaying Potent Antiviral Activity

Design of novel and highly selective SARS-CoV-2 main protease inhibitors

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )

Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation

Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases.

Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease

Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors